Ipsen Appoints Howard Mayer, M.D. as Executive Vice President and Head of Research and Development
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191104006077/en/
Dr. Howard Mayer, Executive Vice-President and Head of Research and Development, effective December 1st, 2019 (Photo: Business Wire)
Ipsen (Euronext: IPN; ADR: IPSEY) today announced the appointment of Dr. Howard Mayer as Executive Vice President and Head of Research and Development, effective December 1st, 2019. He succeeds Dr. Alexandre Lebeaut, Executive Vice President, Research and Development, Chief Scientific Officer, who will retire from the company at the end of the year. Based in Cambridge, Mass, U.S., Dr. Mayer will report directly to David Meek, CEO, Ipsen and serve on the Executive Leadership Team.
David Meek, CEO, Ipsen, commented, “As Ipsen enters its next phase of growth, it is my great pleasure to appoint Dr. Mayer to lead Ipsen’s R&D organization. He brings a wealth of outstanding clinical, medical and leadership experience from a number of global biopharmaceutical companies. Ipsen’s pipeline has never been as rich as it is today, with six Phase 3 or registration trials scheduled for 2020. Dr. Mayer will play a pivotal role in driving our R&D strategy to further grow our pipeline and build a truly differentiated and sustainable portfolio across our key areas of expertise. He will lead the development of innovative therapeutic solutions for our Oncology and Neuroscience franchises including Systemic Radiation Therapy (SRT), while building on our leadership position in neurotoxin research. With extensive experience in rare diseases, Dr. Mayer will also advance our fast-growing Rare Diseases portfolio.”
In his role, Dr. Mayer will work closely with Ipsen’s Business Development team to assess and execute on in-licensing or out-licensing opportunities and build internal expertise accordingly. He will also contribute to the overall management and strategic leadership of the company as a member of the Executive Leadership team. Recognized as an exceptional team leader, Dr. Mayer will be responsible for building a culture centered on collaboration, agility and partnership. By doing so, he will fulfill the company’s vision as a leading global biopharmaceutical company focused on innovation and Specialty Care.
Prior to joining Ipsen, Dr. Mayer was Senior Vice President, Chief Medical Officer and Head of Research and Development, Neuroscience Division, Shire Pharmaceuticals. Dr. Mayer has held several global leadership positions in clinical development and medical affairs with biopharmaceutical companies including EMD Serono, Pfizer and Bristol-Myers Squibb. He obtained his B.A. from the University of Pennsylvania and his M.D. from Albert Einstein College of Medicine in New York, which was followed by an internship and residency at Mount Sinai Hospital and an Infectious Diseases fellowship at Harvard Medical School.
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.2 billion in 2018, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,800 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.fr
Ipsen—Cautionary Note Regarding Forward-Looking Statements
The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes", "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2018 Registration Document available on its website (www.ipsen.com).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Senior Vice President, Global Communications
+33 (0)1 58 33 67 94
Director, Ipsen France Hub, Global Communications
+33 (0) 1 58 33 58 96
Vice President, Investor Relations
+44 (0) 1753 627721
Investor Relations Manager
+33 (0)1 58 33 51 04
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SentinelOne is the Only Vendor to Score Highest Across All Three Gartner Critical Capabilities Use Cases11.5.2021 18:40:00 EEST | Press release
SentinelOne, the autonomous cybersecurity platform company, today announced that Gartner has positioned SentinelOne with the highest scores in all three use cases; Type A, B, & C in Gartner’s 2021 Critical Capabilities for Endpoint Protection Platforms report1. Out of the 19 vendors included in the report, SentinelOne is the only vendor that received the highest score across all three Critical Capabilities use cases: Customer use case Type A is focused on “lean forward” organizations that adopt new technologies very early in the adoption cycle. Customer use case Type B is focused on “overall value” by weighing the risks of the early use of new technology against the benefits. Customer use case Type C represents organizations that typically view technology as an expense or operational necessity and use it as a means to reduce costs. “We believe receiving the highest product score across all three customer use cases in the 2021 Critical Capabilities for Endpoint Protection Platforms vali
1E Challenges DEM Market to Deliver More, Launching New Unified eXperience Management Category11.5.2021 17:35:00 EEST | Press release
1E , innovators in endpoint management, today announced Unified eXperience Management (UXM) , a new category that seeks to address the siloed approach inherent in tools in the Digital Experience Monitoring (DEM) space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005842/en/ 1E Tachyon Platform: Unified eXperience Management to improve the Digital Experience of all employees (Graphic: Business Wire) Due to the relative immaturity of the Digital Experience Management category, most tooling is focused on identifying and reporting on the scale of the problem, scoring, and issue identification. These tools create analytics silos that give insight, but are uncoupled from the automation technology that can actually improve end-user experience at an enterprise scale. Meanwhile, employees are becoming increasingly more frustrated, with 56% feeling dissatisfied with their IT experience. Organizations looking to improve the dig
Biorasi Receives ISO 9001:2015 Certification for Quality Management11.5.2021 17:30:00 EEST | Press release
Biorasi, a leading global full-service contract research organization (CRO), is proud to announce the achievement of ISO 9001:2015 certification. By earning this ISO accreditation, Biorasi has demonstrated dedication to the practice of quality assurance within the clinical trials industry and commitment to quality excellence for individual clinical studies. “ISO 9001:2015 certification is a big deal for Biorasi,” said Chris O’Brien, CEO at Biorasi. “It is a powerful, independent validation of the quality of our processes. It sends a message to potential sponsors across the globe that Biorasi cares deeply about quality. It tells them they can trust us.” Biorasi was presented with their ISO 9001:2015 certification on May 5, 2021, joining the ranks of other quality-focused organizations, including our preferred vendor, IBM Watson Health. “Our Quality Policy is driven by the fundamental understanding that patients and their families are affected by the decisions we make,” said Todd Brill,
Alvotech Seeks to End AbbVie’s Wrongful Monopoly on Humira and Bring Affordable Arthritis Treatment to U.S.11.5.2021 17:23:00 EEST | Press release
Alvotech today filed a federal lawsuit (Case 1:21-cv-00589) seeking to end the monopoly that pharmaceutical giant AbbVie has long-maintained on the adalimumab market, sold as Humira. Humira is the highest grossing prescription drug in the United States with over $16 billion in sales in 2020 (nearly $20Bn globally). Alvotech has developed a biosimilar (analogous to a generic) of Humira called AVT02, the first-filed biosimilar drug equal in strength to Humira’s latest formulation, which AbbVie markets as a high-concentration, pain-free drug. The company is also developing AVT02 as an interchangeable product and it expects results from its ongoing interchangeability study in Q2 of this year. AVT02 could save U.S. taxpayers and the overall healthcare system $8-10 billion annually. “Our new product will be a gamechanger that will provide consumers who are suffering from chronic pain with significant savings, and we look forward to bringing this drug onto the market as soon as possible,” sai
The United Kingdom: Biolog-id and Nicholson Consulting Ltd Cooperate to Develop a Demonstration Lab to Showcase Biolog Transfusion Solution11.5.2021 16:01:00 EEST | Press release
Biolog-id, a global service provider of connected healthcare solutions, and Nicholson Consulting Ltd, an innovative consulting and engineering company specialized in the blood transfusion field, join their forces to set up a demonstration lab located at Malvern Hills Science Park, in the south of Birmingham. This co-branded demo environment will showcase to the UK market the biolog-id’s cutting-edge product-line: Biolog Transfusion Solution. Based on the RFID technology, Biolog Transfusion Solution has been designed to respond to the needs of all the actors involved along the blood transfusion supply chain. By combining software, equipment and tags, this breakthrough innovation offers to manage in real-time each application area, from collection and manufacturing at the blood centre, central and remote inventory at the blood banks to blood compound administration at patient’s bedside. Flexible and reliable, the biolog-id technology generates value throughout the lifecycle of blood prod
Kong Konnect Now Generally Available With Multi-Geo Support: Offers End Users Breakthrough API and Microservices Connectivity11.5.2021 16:00:00 EEST | Press release
Kong Inc., the cloud connectivity company, today announced the general availability release of Kong Konnect, a service connectivity platform that enables the modern connected business. First previewed at Kong Summit 2020 in private beta, Kong Konnect provides end users with instant access to a comprehensive suite of tools that enable reliable, secure and observable connectivity across their APIs and microservices. The GA release features new multi-geo support, allowing users to physically locate services close to their businesses for privacy and regulatory compliance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005311/en/ The fully modular platform enables developers, architects and operators to accelerate application development cycles and provide connectivity between services for stellar digital experiences. Architects decouple connectivity concerns from microservices so that developers can focus on building appli
MagBio Genomics Inc. Develops Automated RNA Purification Chemistry for Mawi iSWAB-RNA v2 on Thermofisher KingFisher™ Flex11.5.2021 16:00:00 EEST | Press release
Mawi DNA Technologies, a biotechnology company focusing on the development of innovative technologies for biosampling, announces that MagBio Genomics has successfully developed an automated RNA purification method for iSWAB-RNA v2 on the Thermofisher KingFisher™ Flex platform with its HighPrep™ Total RNA Isolation Kit - iSWAB™. Mawi DNA Technologies’ iSWAB-RNA v2 allows for non-invasive self collection, concentration, and stabilization of intact buccal cells and/or any mammalian cells collected with a swab or cytobrush. It enables up to four weeks of real-time ambient stabilization of total RNA from the point of collection to processing. The high-quality RNA extracted from stabilized iSWAB-RNA v2 samples is suitable for gene expression applications such as real-time quantitative PCR, reverse transcription PCR, microarrays, northern blot analysis, nuclease protection assays, cDNA library construction and RNA-seq. “Collaborating with MagBio Genomics to optimize their HighPrep™ Total RNA
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom